Cargando…

Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool

BACKGROUND: The endomyocardial biopsy has proven to be an integral diagnostic tool for surveillance of cardiac allograft rejection and identification of myocardial diseases. Nevertheless, this invasive procedure is not risk-free. This study focuses on the risk of complications and diagnostic perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Sławek, Sylwia, Araszkiewicz, Aleksander, Gaczkowska, Agnieszka, Koszarska, Justyna, Celiński, Damian, Grygier, Marek, Lesiak, Maciej, Grajek, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111178/
https://www.ncbi.nlm.nih.gov/pubmed/27846815
http://dx.doi.org/10.1186/s12872-016-0406-0
_version_ 1782467817397813248
author Sławek, Sylwia
Araszkiewicz, Aleksander
Gaczkowska, Agnieszka
Koszarska, Justyna
Celiński, Damian
Grygier, Marek
Lesiak, Maciej
Grajek, Stefan
author_facet Sławek, Sylwia
Araszkiewicz, Aleksander
Gaczkowska, Agnieszka
Koszarska, Justyna
Celiński, Damian
Grygier, Marek
Lesiak, Maciej
Grajek, Stefan
author_sort Sławek, Sylwia
collection PubMed
description BACKGROUND: The endomyocardial biopsy has proven to be an integral diagnostic tool for surveillance of cardiac allograft rejection and identification of myocardial diseases. Nevertheless, this invasive procedure is not risk-free. This study focuses on the risk of complications and diagnostic performance of right ventricular endomyocardial biopsy (EMB). METHODS: In this single-center retrospective study, we analyzed 315 EMB procedures performed between July 2008 and May 2015 in 73 patients. All EMBs were made via the right femoral vein approach under fluoroscopic control to evaluate suspected myocarditis, unclear heart failure, unexplained cardiomyopathy, assumed infiltrative and storage disease or as a part of routine allograft rejection monitoring and clinically suspected rejection diagnosis after heart transplantation (HTx). Obtained specimens were diagnosed histopathologically by one experienced pathologist. All patients underwent a 12-lead electrocardiogram (ECG), ECG monitoring, transthoracic echocardiography before and after EMB to obtain a detailed assessment of the incidence of heart rhythm disorders, pericardial effusions or worsening valve insufficiency. Complications resulting from the procedure were classified as major or minor according to the risk of death. RESULTS: Among all the 315 biopsies, 86.67% were performed in 32 patients after HTx, 3.81% in patients with myocarditis, 2.54% in patients with dilated cardiomyopathy and 1.9% in patients with amyloidosis. The overall complications rate was 1.9% (6 of 315 procedures). Major complications included perforation with pericardial tamponade requiring surgical intervention (0.64%, 2 of 315 procedures). Minor complications included: pericardial effusion (0.32%, 1 of 315 procedures), local hematoma (0.64%, 2 of 315 procedures) and right coronary artery-right ventricle fistula in HTx recipient (0.32%, 1 of 315 procedures). CONCLUSIONS: EMB is a safe procedure with low risk of serious complications and high effectiveness for the evaluation of unexplained left ventricle dysfunction and monitoring allograft rejection after HTx.
format Online
Article
Text
id pubmed-5111178
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51111782016-11-25 Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool Sławek, Sylwia Araszkiewicz, Aleksander Gaczkowska, Agnieszka Koszarska, Justyna Celiński, Damian Grygier, Marek Lesiak, Maciej Grajek, Stefan BMC Cardiovasc Disord Research Article BACKGROUND: The endomyocardial biopsy has proven to be an integral diagnostic tool for surveillance of cardiac allograft rejection and identification of myocardial diseases. Nevertheless, this invasive procedure is not risk-free. This study focuses on the risk of complications and diagnostic performance of right ventricular endomyocardial biopsy (EMB). METHODS: In this single-center retrospective study, we analyzed 315 EMB procedures performed between July 2008 and May 2015 in 73 patients. All EMBs were made via the right femoral vein approach under fluoroscopic control to evaluate suspected myocarditis, unclear heart failure, unexplained cardiomyopathy, assumed infiltrative and storage disease or as a part of routine allograft rejection monitoring and clinically suspected rejection diagnosis after heart transplantation (HTx). Obtained specimens were diagnosed histopathologically by one experienced pathologist. All patients underwent a 12-lead electrocardiogram (ECG), ECG monitoring, transthoracic echocardiography before and after EMB to obtain a detailed assessment of the incidence of heart rhythm disorders, pericardial effusions or worsening valve insufficiency. Complications resulting from the procedure were classified as major or minor according to the risk of death. RESULTS: Among all the 315 biopsies, 86.67% were performed in 32 patients after HTx, 3.81% in patients with myocarditis, 2.54% in patients with dilated cardiomyopathy and 1.9% in patients with amyloidosis. The overall complications rate was 1.9% (6 of 315 procedures). Major complications included perforation with pericardial tamponade requiring surgical intervention (0.64%, 2 of 315 procedures). Minor complications included: pericardial effusion (0.32%, 1 of 315 procedures), local hematoma (0.64%, 2 of 315 procedures) and right coronary artery-right ventricle fistula in HTx recipient (0.32%, 1 of 315 procedures). CONCLUSIONS: EMB is a safe procedure with low risk of serious complications and high effectiveness for the evaluation of unexplained left ventricle dysfunction and monitoring allograft rejection after HTx. BioMed Central 2016-11-15 /pmc/articles/PMC5111178/ /pubmed/27846815 http://dx.doi.org/10.1186/s12872-016-0406-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sławek, Sylwia
Araszkiewicz, Aleksander
Gaczkowska, Agnieszka
Koszarska, Justyna
Celiński, Damian
Grygier, Marek
Lesiak, Maciej
Grajek, Stefan
Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool
title Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool
title_full Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool
title_fullStr Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool
title_full_unstemmed Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool
title_short Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool
title_sort endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111178/
https://www.ncbi.nlm.nih.gov/pubmed/27846815
http://dx.doi.org/10.1186/s12872-016-0406-0
work_keys_str_mv AT sławeksylwia endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool
AT araszkiewiczaleksander endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool
AT gaczkowskaagnieszka endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool
AT koszarskajustyna endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool
AT celinskidamian endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool
AT grygiermarek endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool
AT lesiakmaciej endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool
AT grajekstefan endomyocardialbiopsyviathefemoralaccessstillsafeandvaluablediagnostictool